Literature DB >> 31556357

Identification of KLRC2 as a candidate marker for brain tumor-initiating cells.

Eriko Ishihara1, Satoshi Takahashi1, Raita Fukaya1, Shigeki Ohta2, Kazunari Yoshida1, Masahiro Toda1.   

Abstract

Objective: Brain tumor-initiating cells are characterized by their features of self-renewal, multi-lineage differentiation, and tumorigenicity. We analyzed the gene expression of brain tumor-initiating cells to identify their novel cellular markers.
Methods: We performed cDNA microarray, in silico expressed sequence tags (ESTs), RT-PCR, and q-PCR analyses.
Results: We identified 10 genes that were more highly expressed in brain tumor-initiating cells than in neural stem cells. In addition, we identified 10 other genes that were more highly expressed in brain tumor-initiating cells than in glioma cell line cells from the cDNA microarray analysis. Using the EST database, we looked to see if the 20 genes were expressed more highly in gliomas, compared with normal adult brains. Among the 20 genes, five (KLRC2, HOXB2, KCNJ2, KLRC1, and COL20A1) were expressed more than twice in glioma samples, compared with normal adult brains, and, therefore, were referred for further evaluation. RT-PCR was conducted using cDNA samples obtained from neural stem cells, normal brain tissue, fetal brain tissue, glioma cell lines, and glioma tumor-initiating cell lines. KLRC2, a transmembrane activating receptor in natural killer cells, was expressed more highly in glioma-initiating cells than in neural stem cell lines or normal adult brain tissue. The q-PCR analysis revealed that expression of KLRC2 was significantly higher in brain tumor-initiating cells compared to normal brain controls.
Conclusion: KLRC2 could be a novel cellular marker for brain tumor-initiating cells.

Entities:  

Keywords:  Brain tumor-initiating cell; GBM; KLRC2; cellular marker; glioma

Mesh:

Substances:

Year:  2019        PMID: 31556357     DOI: 10.1080/01616412.2019.1672390

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  3 in total

1.  Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.

Authors:  Nicholas A Vitanza; Matt C Biery; Carrie Myers; Eric Ferguson; Ye Zheng; Emily J Girard; Justyna M Przystal; Giulia Park; Alyssa Noll; Fiona Pakiam; Conrad A Winter; Shelli M Morris; Jay Sarthy; Bonnie L Cole; Sarah E S Leary; Courtney Crane; Nicole A P Lieberman; Sabine Mueller; Javad Nazarian; Raphael Gottardo; Mi-Youn Brusniak; Andrew J Mhyre; James M Olson
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

2.  Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors.

Authors:  Jeppe Thorlacius-Ussing; Christina Jensen; Emilie A Madsen; Neel I Nissen; Tina Manon-Jensen; Inna M Chen; Julia S Johansen; Hadi M H Diab; Lars N Jørgensen; Morten A Karsdal; Nicholas Willumsen
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

3.  Development and Validation of an Immune-Related Gene Pairs Signature in Grade II/III Glioma.

Authors:  Xu Zhang; Shuai Ping; Anni Wang; Can Li; Rui Zhang; Zimu Song; Caibin Gao; Feng Wang
Journal:  Int J Gen Med       Date:  2021-11-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.